阳光生物药店在2024年推出九种非专利药品,扩大了加拿大的市场存在。 Sunshine Biopharma launches nine generic drugs, expanding Canadian market presence in 2024.

以美国为基地的NASDAQ上市制药公司 " 阳光生物药店 " 于2024年推出了九种新的非专利处方药,将其加拿大市场药物数量增加到61种。 Sunshine Biopharma, a US-based NASDAQ-listed pharmaceutical firm, has launched nine new generic prescription drugs in 2024, increasing its Canadian market drug count to 61. 该公司的重点是肿瘤学和抗病毒学等领域的救生药品,目的是扩大其组合,满足各种医疗需求。 The company, focused on life-saving medicines in areas like oncology and antivirals, aims to expand its portfolio and address diverse medical needs. 该公司计划在2024年和2025年进行更多的发射,包括一个与NELASTA类似的生物发射,并正在执行一个专利药物开发方案。 The firm plans additional launches in 2024 and 2025, including a biosimilar of NEULASTA and is conducting a proprietary drug development program.